Emory University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).
Emory University: 1,208 sponsored US clinical trials, 208 recruiting.
Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.
Top-decile sponsor footprint
Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,208 total, page 1 of 25
MDMA-Assisted Massed Exposure Therapy for PTSD
NCT07288151
Thrive With Type 1 Diabetes 2026
NCT07522866
The PREVENT Resilience Study
NCT07568145
Parent-Mediated Telehealth Intervention for Insomnia in Young Autistic Children
NCT07435740
Comprehensive Toileting Program
NCT07226739
Diabetes Multimorbidity Typology, Trajectory, and Feasibility of an Audio Diary Mobile Application to Support Self-management
NCT07474376
ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)
NCT07559903
Inspiring Seniors Towards Exercise Promotion - 2
NCT07629739
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
NCT07405476
Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease
NCT06979492
Handgrip Exercise Training and CKD
NCT07094906
Effectiveness- Implementation Trial of the Function-Based Elopement Treatment
NCT07194083
Opioid-Sparing Joint Replacement
NCT07348627
Zesty Exercise System for Therapeutic Engagement
NCT07382674
Collaborative Learning to Achieve Refined Interventions for Emory: Kidney Disease
NCT06693661
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
NCT04563520
Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
NCT06492954
Optimizing Strategies to Maximize Patient Recruitment Yield
NCT07290335
Reboot Pain (tDCS)
NCT07411859
PKU Protein Requirements
NCT07194993
Effect of Product Characteristics on the Abuse Liability of Nicotine Pouches
NCT07165808
Visual Influences on Vestibular Adaptation
NCT07380256
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
NCT07144254
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
NCT07174570
GAMES Intervention in MCI (Mild Cognitive Impairment)
NCT07296133
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
NCT06324240
Efficacy of EXPAREL vs. Bupivacaine
NCT07212114
Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment
NCT07112690
Addressing Health Literacy With a Tailored Survivorship Care Plan
NCT06674863
MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults
NCT07197762
Rise With Resilience
NCT07217275
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
NCT07155317
Got Doxy- 'Flipping the Script' on STI PEP
NCT07215325
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
NCT06492759
Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions
NCT07213154
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
NCT07150546
Dysphagia Study Using Novel Microphone Device
NCT07251140
Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation
NCT07223268
Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)
NCT07136857
Cranial Electrotherapy Stimulation and Brain Imaging for Gulf War Syndrome
NCT07151248
CCSH (Compassion-Centered Spiritual Health) for Teams
NCT06722027
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
NCT07101445
Weyera Mental Health Pilot Intervention
NCT06960187
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
NCT07140679
Sisters of Heart (Hermanas de Corazón): A Community Health Worker Initiative for Improving Heart Health in Migrant Farmworker Women
NCT07111026
Deconstructing Voice Therapy: Towards Enhanced Communication Outcomes
NCT07176988
Evaluating Georgia Part C Implementation Outcomes
NCT07148258
JAK Signaling in Depression
NCT07003997
An Individualized Online Home-Based Exercise Program for Improving Symptoms in Gynecologic Cancer Survivors
NCT06709534
Caregiver Bootcamp
NCT07006116
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 154 |
| Phase 2 | 190 |
| Phase 3 | 36 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Emory University pipeline
208 recruiting of 1,208 indexed (17% open); 767 completed (63%).
Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).
Top condition: Depression (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Emory University: open-pipeline peers nationwide
Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,208 trials (± recruiting share)
- Northwestern University · 1,209 trials · 15% recruiting
- University of Pittsburgh · 1,238 trials · 13% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Baylor Research Institute · 17% recruiting · 180 trials
- National Institute on Alcohol Abuse and Alcoholism (NIAAA) · 17% recruiting · 93 trials
- Hunter College of City University of New York · 17% recruiting · 29 trials
- Ochsner Health System · 17% recruiting · 29 trials
Related
What to do with this Emory University page
1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.
- 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Emory University pipeline card: 1,208 registered trials from official public datasets.Report a data error.